Diagnostic evaluation of patients suspected to have collagen lysyl hydroxylase deficiency (Ehlers-Danlos Syndrome type VIA). May be useful when evaluating bone resorption (eg, osteoporosis). Preferred test for monitoring bone resorption and response to antiresorptive therapy is C-Telopeptide, Beta-Cross-Linked, Serum (0070416).
High Performance Liquid Chromatography (HPLC)
New York DOH Approval Status
First morning void.
Transfer 8 mL urine to ARUP Standard Transport Tubes. (Min: 4 mL)
Ambient: Unacceptable; Refrigerated: 1 week; Frozen: 6 months
|0-11 months||353-560 µmol/mol crt||46-113 µmol/mol crt||0.13-0.20|
|1-3 years||108-400 µmol/mol crt||19-94 µmol/mol crt||0.18-0.24|
|4-9 years||117-325 µmol/mol crt||20-75 µmol/mol crt||0.19-0.25|
|10-14 years||81-267 µmol/mol crt||13-61 µmol/mol crt||0.17-0.27|
|15-19 years||38-80 µmol/mol crt||10-18 µmol/mol crt||0.20-0.26|
|20 years and older||20-40 µmol/mol crt||5-11 µmol/mol crt||0.23-0.29|
Pyridinoline and Deoxypyridinoline excretion follows a circadian rhythm. Reference intervals have been established on first morning void urine samples.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|0080347||PYD and DPD Interpretation|
- Deoxypyridinoline and Pyridinoline, HPLC